MeiraGTx Holdings plc (MGTX) stock
MGTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 13/3065% below fair value
$8.32−0.14 (-1.65%)
Close on Nov 18, 2026Market cap $799.08MP/E 11.7Yield –
MeiraGTx EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
MeiraGTx's EPS for the twelve months ending Jun 30, 2026 was $0.71. For fiscal 2025 it was -$1.42. The highest annual figure on record is -$1.42 in fiscal 2025.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$1.42 | – |
| FY2024 | Dec 31, 2024 | -$2.12 | – |
| FY2023 | Dec 31, 2023 | -$1.49 | – |
| FY2022 | Dec 31, 2022 | -$2.87 | – |
| FY2021 | Dec 31, 2021 | -$1.80 | – |
| FY2020 | Dec 31, 2020 | -$1.54 | – |
| FY2019 | Dec 31, 2019 | -$1.65 | – |
| FY2018 | Dec 31, 2018 | -$4.47 | – |
| FY2017 | Dec 31, 2017 | -$3.72 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.71 | – |
| Q1 FY2026 | Mar 31, 2026 | -$0.57 | – |
| Q4 FY2025 | Dec 31, 2025 | $0.19 | – |
| Q3 FY2025 | Sep 30, 2025 | -$0.62 | – |
| Q2 FY2025 | Jun 30, 2025 | -$0.48 | – |
| Q1 FY2025 | Mar 31, 2025 | -$0.51 | – |
| Q4 FY2024 | Dec 31, 2024 | -$0.50 | -256.3% |
| Q3 FY2024 | Sep 30, 2024 | -$0.55 | – |
| Q2 FY2024 | Jun 30, 2024 | -$0.76 | – |
| Q1 FY2024 | Mar 31, 2024 | -$0.32 | – |
| Q4 FY2023 | Dec 31, 2023 | $0.32 | – |
| Q3 FY2023 | Sep 30, 2023 | -$0.74 | – |
| Q2 FY2023 | Jun 30, 2023 | -$0.53 | – |
| Q1 FY2023 | Mar 31, 2023 | -$0.62 | – |
| Q4 FY2022 | Dec 31, 2022 | -$0.58 | – |
| Q3 FY2022 | Sep 30, 2022 | -$0.83 | – |
| Q2 FY2022 | Jun 30, 2022 | -$0.76 | – |
| Q1 FY2022 | Mar 31, 2022 | -$0.70 | – |
| Q4 FY2021 | Dec 31, 2021 | -$0.22 | – |
| Q3 FY2021 | Sep 30, 2021 | -$0.59 | – |
| Q2 FY2021 | Jun 30, 2021 | -$0.46 | – |
| Q1 FY2021 | Mar 31, 2021 | -$0.54 | – |
| Q4 FY2020 | Dec 31, 2020 | -$0.26 | – |
| Q3 FY2020 | Sep 30, 2020 | -$0.17 | – |
| Q2 FY2020 | Jun 30, 2020 | -$0.69 | – |
| Q1 FY2020 | Mar 31, 2020 | -$0.43 | – |
| Q4 FY2019 | Dec 31, 2019 | -$0.15 | – |
| Q3 FY2019 | Sep 30, 2019 | -$0.30 | – |
| Q2 FY2019 | Jun 30, 2019 | -$0.63 | – |
| Q1 FY2019 | Mar 31, 2019 | -$0.62 | – |
| Q3 FY2018 | Sep 30, 2018 | -$0.59 | – |
| Q2 FY2018 | Jun 30, 2018 | -$2.29 | – |
| Q1 FY2018 | Mar 31, 2018 | -$1.91 | – |
| Q4 FY2017 | Dec 31, 2017 | -$1.06 | – |
| Q3 FY2017 | Sep 30, 2017 | -$1.00 | – |
| Q2 FY2017 | Jun 30, 2017 | -$0.85 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?